A major limitation of the previous studies is their case-control and retrospective design. To date, no study has prospectively examined the clinical utility of CYP450 polymorphism genotyping in psychosis. Therefore, we will conduct a prospective study in which patients with psychosis undergo CYP450 genotyping at study entry, and antipsychotic drug dosage is determined by CYP2D6 genotype.